Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 303791, 10 pages
http://dx.doi.org/10.1155/2015/303791
Research Article

Low Mutational Burden of Eight Genes Involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 Pathways in Female Genital Tract Primary Melanomas

1First Department of Obstetrics and Gynecology, University of Athens School of Medicine, Alexandra Hospital, 11528 Athens, Greece
2Laboratory of Biology, Department of Basic Medical Sciences, University of Athens School of Medicine, 11527 Athens, Greece
3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece
4Laboratory of Histopathology and Cytopathology, Department of Pathology, Henry Dunant Hospital, 11527 Athens, Greece

Received 4 September 2014; Accepted 6 November 2014

Academic Editor: Gérald E. Piérard

Copyright © 2015 Kalliopi I. Pappa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Mihajlovic, S. Vlajkovic, P. Jovanovic, and V. Stefanovic, “Primary mucosal melanomas: a comprehensive review,” International Journal of Clinical and Experimental Pathology, vol. 5, no. 8, pp. 739–753, 2012. View at Google Scholar · View at Scopus
  2. R. D. Carvajal, S. A. Spencer, and W. Lydiatt, “Mucosal melanoma: a clinically and biologically unique disease entity,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 3, pp. 345–356, 2012. View at Google Scholar · View at Scopus
  3. T. Gungor, S. O. Altinkaya, M. Ozat, H. Bayramoglu, and L. Mollamahmutoglu, “Primary malignant melanoma of the female genital tract,” Taiwanese Journal of Obstetrics and Gynecology, vol. 48, no. 2, pp. 169–175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. G. Bradgate, T. P. Rollason, C. C. McConkey, and J. Powell, “Malignant melanoma of the vulva: a clinicopathological study of 50 women,” British Journal of Obstetrics and Gynaecology, vol. 97, no. 2, pp. 124–133, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. G. L. Phillips, B. N. Bundy, T. Okazaki, P. R. Kucera, and F. B. Stehman, “Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group,” Cancer, vol. 73, no. 10, pp. 2626–2632, 1994. View at Google Scholar
  6. G. Raber, V. Mempel, C. Jackisch et al., “Malignant melanoma of the vulva. Report of 89 patients,” Cancer, vol. 78, no. 11, pp. 2353–2358, 1996. View at Google Scholar
  7. W. P. Irvin Jr., R. L. Legallo, M. H. Stoler, L. W. Rice, P. T. Taylor Jr., and W. A. Andersen, “Vulvar melanoma: a retrospective analysis and literature review,” Gynecologic Oncology, vol. 83, no. 3, pp. 457–465, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. B. K. Ragnarsson-Olding, “Primary malignant melanoma of the vulva: an aggressive tumor for modeling the genesis of non-UV light-associated melanomas,” Acta Oncologica, vol. 43, no. 5, pp. 421–435, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Hocker and H. Tsao, “Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants,” Human Mutation, vol. 28, no. 6, pp. 578–588, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. W. J. Tcheung, M. A. Selim, J. E. Herndon II, A. P. Abernethy, and K. C. Nelson, “Clinicopathologic study of 85 cases of melanoma of the female genitalia,” Journal of the American Academy of Dermatology, vol. 67, no. 4, pp. 598–605, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. M. Pollock, U. L. Harper, K. S. Hansen et al., “High frequency of BRAF mutations in nevi,” Nature Genetics, vol. 33, no. 1, pp. 19–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Platz, S. Egyhazi, U. Ringborg, and J. Hansson, “Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site,” Molecular Oncology, vol. 1, no. 4, pp. 395–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Davies and Y. Samuels, “Analysis of the genome to personalize therapy for melanoma,” Oncogene, vol. 29, no. 41, pp. 5545–5555, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Edlundh-Rose, S. Egyházi, K. Omholt et al., “NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing,” Melanoma Research, vol. 16, no. 6, pp. 471–478, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson, “NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression,” Clinical Cancer Research, vol. 9, no. 17, pp. 6483–6488, 2003. View at Google Scholar · View at Scopus
  17. H. Tsao, V. Goel, H. Wu, G. Yang, and F. G. Haluska, “Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma,” Journal of Investigative Dermatology, vol. 122, no. 2, pp. 337–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Omholt, D. Kröckel, U. Ringborg, and J. Hansson, “Mutations of PIK3CA are rare in cutaneous melanoma,” Melanoma Research, vol. 16, no. 2, pp. 197–200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Curtin, M. S. Stark, D. Pinkel, N. K. Hayward, and B. C. Bastian, “PI3-kinase subunits are infrequent somatic targets in melanoma,” Journal of Investigative Dermatology, vol. 126, no. 7, pp. 1660–1663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. D. van Raamsdonk, K. G. Griewank, M. B. Crosby et al., “Mutations in GNA11 in uveal melanoma,” The New England Journal of Medicine, vol. 363, no. 23, pp. 2191–2199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian, “Somatic activation of KIT in distinct subtypes of melanoma,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4340–4346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Hirota, K. Isozaki, Y. Moriyama et al., “Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors,” Science, vol. 279, no. 5350, pp. 577–580, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Satzger, T. Schaefer, U. Kuettler et al., “Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas,” British Journal of Cancer, vol. 99, no. 12, pp. 2065–2069, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Omholt, E. Grafström, L. Kanter-Lewensohn, J. Hansson, and B. K. Ragnarsson-Olding, “KIT pathway alterations in mucosal melanomas of the vulva and other sites,” Clinical Cancer Research, vol. 17, no. 12, pp. 3933–3942, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Ogawa, C. Sun, and A. Horii, “Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade,” Oncology Reports, vol. 14, no. 6, pp. 1481–1485, 2005. View at Google Scholar · View at Scopus
  26. R. H. Edwards, M. R. Ward, H. Wu et al., “Absence of BRAF mutations in UV-protected mucosal melanomas,” Journal of Medical Genetics, vol. 41, no. 4, pp. 270–272, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. C. W. Wong, Y. S. Fan, T. L. Chan et al., “BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs,” Journal of Clinical Pathology, vol. 58, no. 6, pp. 640–644, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Curtin, J. Fridlyand, T. Kageshita et al., “Distinct sets of genetic alterations in melanoma,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2135–2147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. Y.-Z. Feng, T. Shiozawa, T. Miyamoto et al., “BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression,” Clinical Cancer Research, vol. 11, no. 17, pp. 6133–6138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J. L. Benedet, H. Bender, H. Jones III, H. Y. Ngan, and S. Pecorelli, “FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology,” International Journal of Gynecology and Obstetrics, vol. 70, no. 2, pp. 209–262, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Edge, D. R. Byrd, C. C. Compton et al., AJCC Cancer Staging Manual, Springer, New York, NY, USA, 7th edition, 2010.
  32. K. I. Pappa, M. Choleza, S. Markaki et al., “Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status,” Gynecologic Oncology, vol. 100, no. 3, pp. 596–600, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Ikenoue, Y. Hikiba, F. Kanai et al., “Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis,” Cancer Genetics and Cytogenetics, vol. 149, no. 1, pp. 68–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M. N. Nikiforova, R. A. Lynch, P. W. Biddinger et al., “RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2318–2326, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Samuels, Z. Wang, A. Bardelli et al., “High frequency of mutations of the PIK3CA gene in human cancers,” Science, vol. 304, no. 5670, p. 554, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Bauer, E. Kilic, J. Vaarwater, B. C. Bastian, C. Garbe, and A. de Klein, “Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma,” British Journal of Cancer, vol. 101, no. 5, pp. 813–815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. D. Tacastacas, J. Bray, Y. K. Cohen et al., “Update on primary mucosal melanoma,” Journal of the American Academy of Dermatology, vol. 71, no. 2, pp. 366–375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Tseng, J. Kim, A. Warrick et al., “Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract,” Journal of the American Academy of Dermatology, vol. 71, no. 2, pp. 229–236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Aulmann, H. P. Sinn, R. Penzel et al., “Comparison of molecular abnormalities in vulvar and vaginal melanomas,” Modern Pathology, vol. 27, pp. 1386–1393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Langer, K. Becker, M. Feith, H. Friess, H. Höfler, and G. Keller, “Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases,” Modern Pathology, vol. 24, no. 4, pp. 495–501, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. C. D. van Raamsdonk, V. Bezrookove, G. Green et al., “Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi,” Nature, vol. 457, no. 7229, pp. 599–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Ambrosini, C. A. Pratilas, L.-X. Qin et al., “Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance,” Clinical Cancer Research, vol. 18, no. 13, pp. 3552–3561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Lamba, L. Felicioni, F. Buttitta et al., “Mutational profile of GNAQQ209 in human tumors,” PLoS ONE, vol. 4, no. 8, Article ID e6833, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Y. Kim, D. W. Kim, K. Kim, J. Curry, C. Torres-Cabala, and S. Patel, “GNAQ mutation in a patient with metastatic mucosal melanoma,” BMC Cancer, vol. 14, no. 14, article 516, 2014. View at Google Scholar
  45. M. Dovey, R. M. White, and L. I. Zon, “Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish,” Zebrafish, vol. 6, no. 4, pp. 397–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Hodis, I. R. Watson, G. V. Kryukov et al., “A landscape of driver mutations in melanoma,” Cell, vol. 150, no. 2, pp. 251–263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Sekulic, P. Haluska Jr., A. J. Miller et al., “Malignant melanoma in the 21st century: the emerging molecular landscape,” Mayo Clinic Proceedings, vol. 83, no. 7, pp. 825–846, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Young, D. Lou, and F. McCormick, “Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling,” Cancer Discovery, vol. 3, no. 1, pp. 112–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. M. F. Berger, E. Hodis, T. P. Heffernan et al., “Melanoma genome sequencing reveals frequent PREX2 mutations,” Nature, vol. 485, no. 7399, pp. 502–506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. S. J. Furney, S. Turajlic, G. Stamp et al., “Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma,” Journal of Pathology, vol. 230, no. 3, pp. 261–269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Yen, R. M. White, D. C. Wedge et al., “The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models,” Genome Biology, vol. 14, no. 10, article R113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Davies, “The role of the PI3K-AKT pathway in melanoma,” Cancer Journal, vol. 18, no. 2, pp. 142–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Shpitz, E. Klein, P. Malinger et al., “Altered expression of the DNA mismatch repair proteins hMLH1 and hMSH2 in cutaneous dysplastic nevi and malignant melanoma,” The International Journal of Biological Markers, vol. 20, no. 1, pp. 65–68, 2005. View at Google Scholar · View at Scopus
  54. J. Shia, Z. Stadler, M. R. Weiser et al., “Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?” The American Journal of Surgical Pathology, vol. 35, no. 3, pp. 447–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. The Cancer Genome Atlas Research Network, “Comprehensive molecular profiling of lung adenocarcinoma,” Nature, vol. 511, no. 7511, pp. 543–550, 2014. View at Google Scholar